ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 3
Panelists discuss how the interim results from the phase 3 ADRIATIC trial demonstrate significant overall survival and progression-free survival benefits for patients with limited-stage small cell lung cancer following concurrent chemoradiotherapy, highlighting the potential clinical relevance of durvalumab in improving life expectancy and its mechanisms of synergy within the tumor microenvironment.
This is a modal window.
Video content above is prompted by the following:
Dr Leal: Please discuss the interim results from the phase 3 ADRIATIC trial, which evaluated durvalumab in patients with limited-stage small cell lung cancer (LS-SCLC) who did not experience disease progression following concurrent chemoradiotherapy (cCRT) vs placebo after cCRT.
Dr Sen: How might the statistically significant overall survival and progression-free survival outcomes reported in ADRIATICtranslate into a clinically relevant improvement in life expectancy for your patients with LS-SCLC that has not progressed after cCRT?